Ovid Technologies Email Format
Book and Periodical PublishingUnited States51-200 Employees
Ovid Technologies is a U.S.-based publisher operating in the book and periodical sector, with a focus on medical and scholarly content delivered through a research platform. The platform provides access to research articles, books, and media to support academic and clinical inquiry. In 2022, the platform expanded to include a Diversity, Equity and Inclusion collection. Additionally, the company has pursued licensing and collaboration opportunities, such as an option agreement with Healx for an exclusive license to gaboxadol (OV101) in 2022. The company is part of the United States publishing landscape and concentrates on medical and scholarly content delivery. It has engaged in collaborations with pharmaceutical firms, including a past partnership with Takeda Pharmaceuticals tied to pediatric epilepsy drug trials.